Skip Navigation Henry, transplant recipient

Marrow transplant patients are at the heart of our mission.

Do a world of good with every mile you ride.

Join us on September 10 from 12-1:15 p.m. CT. for a free telephone education workshop. Learn about the basics of stem cell transplant, HLA matching, how a doctor searches for a donor, caregiver and survivor experiences and resources available to patients.

Register today

Every four minutes, someone is diagnosed with a blood cancer like leukemia. It can happen to anyone, at any time. But so can a curea marrow or cord blood transplant. Learn more about the heart of our missiondelivering cures for blood cancersin our 2013 Report to the Community.

Learn more

Your little miracle could be someone elses cure. Your babys umbilical cord is a lifeline. After your baby is born, that lifeline can give hope to patients with blood cancers. Learn more about donating cord blood and how cord blood saves lives.

Learn more

Be The Match Community: The power of one. The power of many. Mission advocates for patients with blood cancers. Visit us on Facebook.

Visit link:
Be The Match donate marrow & cord blood, transplant ...

18 hours ago

Anyone who has suffered an injury can probably remember the after-effects, including pain, swelling or redness. These are signs that the body is fighting back against the injury. When tissue in the body is damaged, biological programs are activated to aid in tissue regeneration. An inflammatory response acts as a protective mechanism to enable repair and regeneration, helping the body to heal after injuries such as wounds and burns. However, the same mechanism may interfere with healing in situations in which foreign material is introduced, for example when synthetics are grafted to skin for dermal repair. In such cases, the inflammation may lead to tissue fibrosis, which creates an obstacle to proper physiological function.

The research group of Arun Sharma, PhD has been working on innovative approaches to tissue regeneration in order to improve the lives of patients with urinary bladder dysfunction. Among their breakthroughs was a medical model for regenerating bladders using stem cells harvested from a donor's own bone marrow, reported in the Proceedings of the National Academy of Sciences in 2013.

More recently, the team has developed a system that may protect against the inflammatory reaction that can negatively impact tissue growth, development and function. Self-assembling peptide amphiphiles (PAs) are biocompatible and biodegradable nanomaterials that have demonstrated utility in a wide range of settings and applications. Using an established urinary bladder augmentation model, the Sharma Group treated a highly pro-inflammatory biologic scaffold used in a wide array of settings with anti-inflammatory peptide amphiphiles (AIF-PAs). When compared with control PAs, the treated scaffold showed regenerative capacity while modulating the innate inflammatory response, resulting in superior bladder function.

This work is published in the journal Biomaterials. Says Sharma, "Our findings are very relevant not just for bladder regeneration but for other types of tissue regeneration where foreign materials are utilized for structural support. I also envision the potential utility of these nanomolecules for the treatment of a wide range of dysfunctional inflammatory based conditions."

Explore further: Taking tissue regeneration beyond state-of-the-art

More information: Bury MI, Fuller NJ, Meisner JW, Hofer MD, Webber MJ, Chow LW, Prasad S, Thaker H, Yue X, Menon VS, Diaz EC, Stupp SI, Cheng EY, Sharma AK. The promotion of functional urinary bladder regeneration using anti-inflammatory nanofibers. Biomaterials. Available online 18 August 2014. http://www.sciencedirect.com/science/ ii/S0142961214008667

Journal reference: Proceedings of the National Academy of Sciences Biomaterials

Provided by Children's Memorial Hospital

A new approach to bladder regeneration is capitalizing on the potential of two distinct cell populations harvested from a patient's healthy bone marrow, a new study reports.

More:
Tissue regeneration using anti-inflammatory nanomolecules

HOWARD, Wis. -- A northeastern Wisconsin girl, who would have died without a bone marrow transplant, has finally met the man whose donation saved her life.

About three years ago, Mira Erdmann was diagnosed with an auto-immune disease that affects about one in a million people. Doctors said a bone marrow transplant was the Howard girl's only chance of survival.

Christian Werth of Germany found out he was Mira's match just three months after he became a donor, WBAY-TV reported.

"That brought me tears. I sat at home. I called my wife. She was at work, and I told her, I said 'It was for a little girl,' " Werth said.

His stem cells were harvested and sent to Mira's doctors in the U.S. Mira received the transplant and pulled through despite several complications and a tentative outcome.

"My part was the smallest one, but it's cool to see that she's now so happy and healthy after all that," Werth said.

The Werths and the Erdmanns initially communicated through letters because registry rules require anonymity for two years.

"When we received letters, there was something blacked out or it was something made to where we couldn't read it," Werth said. "We took a flashlight behind to find some information!"

Werth and his wife flew to Wisconsin to meet with the Erdmanns this week.

"It was almost surreal, because we had been chatting with him on Skype since December, so to see him in person, I thought I would never let him go," Mira's mother, Tania Erdmann, said. "We cried and we hugged, and it was just really emotional."

Original post:
Wisconsin girl meets marrow donor who saved her life

Chemotherapy and Radiation Therapy

Before you get the stem cell transplant, youll get the actual cancer treatment. To destroy the abnormal stem cells, blood cells, and cancer cells your doctor will give you high doses of chemotherapy, radiation therapy, or both. In the process, the treatment will kill healthy cells in your bone marrow, essentially making it empty. Your blood counts (number of red blood cells, white blood cells, and platelets) will drop quickly. Since chemotherapy and radiation can cause nausea and vomiting, you might need anti-nausea drugs.

Without bone marrow, your body is vulnerable. You won't have enough white blood cells to protect you from infection. So during this time, you might be isolated in a hospital room or required to stay at home until the new bone marrow starts growing. You might also need transfusions and medication to keep you healthy.

A few days after youve finished with your chemotherapy or radiation treatment, your doctor will order the actual stem cell transplant. The harvested stem cells -- either from a donor or from your own body -- are thawed and infused into a vein through an IV tube. The process is essentially painless. The actual stem cell transplant is similar to a blood transfusion. It takes one to five hours.

The stem cells then naturally move into the bone marrow. The restored bone marrow should begin producing normal blood cells after several days, or up to several weeks later.

The amount of time youll need to be isolated will depend on your blood counts and general health. When you are released from the hospital or from isolation at home, your transplant team will provide you with specific instructions on how to care for yourself and prevent infections. Youll also learn what symptoms need to be checked out immediately. Full recovery of the immune system might take months or even years. Your doctor will need to do tests to check on how well your new bone marrow is doing.

There are also variations in the stem cell transplant process being studied in clinical trials. One approach is called a tandem transplant, in which a person would get two rounds of chemotherapy and two separate stem cell transplants. The two transplants are usually done within six months of one another.

Another is called a mini-transplant, in which doctors use lower doses of chemotherapy and radiation. The treatment is not strong enough to kill all of the bone marrow -- and it wont kill all of the cancer cells either. However, once the donated stem cells take hold in the bone marrow, they produce immune cells that might attack and kill the remaining cancer cells. This is also called a non-myeloablative transplant.

View post:
Bone Marrow Transplants and Stem Cell Transplants for ...

A team of chemical engineers from MIT has developed a new method of stimulating bone growth, by utilizing the same chemical processes that occur naturally in the human body following an injury such as a broken or fractured bone. The technique involves the insertion of a porous scaffold coated with growth factors that prompt the body's own cells to naturally mend the damaged or deformed bone.

Current techniques for replacing or mending damaged bone often include a bone transplant from another area of the patient's body. This is an expensive, painful, and often inadequate option for treatment, as it is difficult to harvest enough bone to successfully treat the wound. Due to the inadequacies of the current forms of bone replacement treatment, a number of scaffold-based approaches are in development, however few are as promising as the tissue scaffold presented by the team from MIT.

The new method would seek to mimic the natural steps taken by the human body to encourage bone growth without the unpleasant necessity of extracting further bone from the patient's body. After a break or fracture, the body releases both platelet-derived growth factors, (PDGF) and bone morphogenetic protein 2 (BMP-2), in order to stimulate natural bone regeneration. These factors essentially recruit other immature cells, coaxing them to become osteoblasts, a cell type with the capacity to create new bone. At the same time, the PDFG and BMP-2 provide a supporting structure around which the bone can be rebuilt.

The 0.1 mm-thick polymer scaffold sheet developed by the scientists from MIT would appear to successfully mimic this biological process, releasing the growth factors in the correct order and quantity, essentially tricking the body into thinking it had initiated the healing process itself. Previous attempts at biomimicry in this area have failed due to an inability to release the growth factors in a natural and controlled fashion, causing the body to clear the factors away from the wound before they could have any substantial healing effect.

The scaffold has the potential to do away with the painful, invasive procedures currently used to repair/replace bone (Image: MIT)

"You want the growth factor to be released very slowly and with nanogram or microgram quantities, not milligram quantities," States Paula Hammond, member of MIT's Koch Institute for Integrative Cancer Research and Department of Engineering, and senior author on the paper outlining the results of the study. "You want to recruit these native adult stem cells we have in our bone marrow to go to the site of injury and then generate bone around the scaffold, and you want to generate a vascular system to go with it."

The measured release of growth factors is achieved by layering the porous scaffold with around 40 layers of BMP-2, followed by another 40 layers of PDGF. Once the layering process is complete, medical practitioners can cut out segments of the scaffold, tailoring the treatment to fit any size of wound. Furthermore, once the treatment has run its course and the bone has been regrown, the biodegradable scaffold is safely adsorbed into the body, leaving no harmful traces as a by-product of the procedure.

The scaffold has been tested in the lab by administering the treatment to rats with skull deficiencies too large to be healed without the aid of outside stimuli. It was found that the initial release of the PDGF created a healing cascade, mobilizing cells important to the rebuilding process to move to the site of the deformity. The BMP-2 then went to work inducing a number of the cells to become osteoblasts, which would go on to create the new bone.

Only two weeks after the initial transplant, it was found that fresh bone had been created that was indistinguishable in nature from the natural bone found in the surrounding areas of the skull. Looking to the future, the team hopes to test the technique on larger animals, with the long-term goal of advancing to clinical trials.

A paper covering the research carried out by the team from MIT has been published in the journal Proceedings of the National Academy of Sciences of the United States of America.

Read the original post:
MIT scientists use polymer scaffold to stimulate bone growth

Ruxolitinib (trade name: Jakavi) has been approved since August 2012 for the treatment of adults with myelofibrosis. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over the appropriate comparator therapy specified by the Federal Joint Committee (G-BA).

According to the results, there is an indication of considerable added benefit in comparison with "best supportive care" (BSC) because ruxolitinib is better at relieving symptoms. Moreover, a hint of an added benefit with regard to survival can be derived from the dossier. Its extent is non-quantifiable, however.

Bone marrow is replaced by connective tissue

Myelofibrosis is a rare disease of the bone marrow, in which the bone marrow is replaced by connective tissue. As a consequence of this so-called fibrosis, the bone marrow is no longer able to produce enough blood cells. Sometimes the spleen or the liver takes over some of the blood production. Then these organs enlarge and can cause abdominal discomfort and pain. The typical symptoms also include feeling of fullness, night sweats and itching. Some patients with myelofibrosis develop leukemia.

Stem cell transplantation is currently the only option to cure myelofibrosis. The drug ruxolitinib aims to relieve the symptoms of myelofibrosis.

G-BA specifies appropriate comparator therapy

Ruxolitinib is an option for patients with so-called primary or secondary myelofibrosis whose spleen is already enlarged (splenomegaly) or who have other disease-related symptoms.

The G-BA specified "best supportive care" (BSC) as appropriate comparator therapy. BSC means a therapy that provides the patient with the best possible, individually optimized, supportive treatment to alleviate symptoms and improve quality of life. This also includes adequate pain therapy.

Relevant study ongoing until 2015

In its assessment, IQWiG could include one randomized controlled trial (RCT) conducted in 89 centres in Australia, Canada and the United States (COMFORT-I). The 309 patients in total were either treated with ruxolitinib plus BSC or with placebo plus BSC.

Follow this link:
Ruxolitinib for myelofibrosis: Indication of considerable added benefit

By Estel Grace Masangkay

With help from the zebrafish, a team of Australian researchers has uncovered how hematopoietic stem cells (HSC) renew themselves, considered by many to be the holy grail of stem cell research.

HSCs are a significant type of stem cell present in the blood and bone marrow. These are needed for the replenishment of the bodys supply of blood and immune cells. HSCs already play a part in transplants in patients with blood cancers such as leukemia and myeloma. The stem cells are also studied for their potential to transform into vital cells including muscle, bone, and blood vessels.

Understanding how HSCs form and renew themselves has potential application in the treatment of spinal cord injuries, degenerative disorders, even diabetes. Professor Peter Currie, of the Australian Regenerative Medicine Institute at Victorias Monash University, led a research team to discover a crucial part of HSCs development. Using a high-resolution microscopy, Prof. Curies team caught HSCs on film as they formed inside zebrafish embryos. The discovery was made while the researchers were studying muscle mutations in the aquatic animal.

Zebrafish make HSCs in exactly the same way as humans do, but whats special about these guys is that their embryos and larvae develop free living and not in utero as they do in humans. So not only are these larvae free-swimming, but they are also transparent, so we could see every cell in the body forming, including HSCs, explained Prof. Currie.

While playing the film back, the researchers noticed that a buddy cell came along to help the HSCs form. Called endotome cells, they aided pre-HSCs to turn into HSCs. Prof. Currie said, Endotome cells act like a comfy sofa for pre-HSCs to snuggle into, helping them progress to become fully fledged stem cells. Not only did we identify some of the cells and signals required for HSC formation, we also pinpointed the genes required for endotome formation in the first place.

The next step for the researchers is to locate the signals present in the endotome cells that trigger HSC formation in the embryo. This can help scientists make different blood cells on demand for blood-related disorders. Professor Currie also pointed out the discoverys potential for correcting genetic defects in the cell and transplanting them back in the body to treat disorders.

The teams work was published in the international journal Nature.

The rest is here:
Stem Cell Research Holy Grail' Uncovered, Thanks to Zebrafish

Contact Information

Available for logged-in reporters only

Newswise A new study by Barbara Beltz, the Allene Lummis Russell Professor of Neuroscience at Wellesley College, and Irene Sderhll of Uppsala University, Sweden, published in the August 11 issue of the journal Developmental Cell, demonstrates that the immune system can produce cells with stem cell properties, using crayfish as a model system. These cells can, in turn, create neurons in the adult animal. The flexibility of immune cells in producing neurons in adult animals raises the possibility of the presence of similar types of plasticity in other animals.

We have been suspicious for some time that the neuronal precursor cells (stem cells) in crayfish were coming from the immune system, Beltz wrote. The paper contains multiple lines of evidence that support this conclusion, in addition to the experiments showing that blood cells transferred from a donor to a recipient animal generate neurons.

Beltz, whose research focuses on the production of new neurons in the adult nervous system, uses the crustacean brain as the model system because the generations of precursor cells are spatially segregated from one another. According to Beltz, this separation is crucial because it allowed the researchers to determine that the first generation precursors do not self-renew. For the Developmental Cell study, the cells of one crayfish were labeled and this animals blood was used for transfusions into another crayfish. They found that the donor blood cells could generate neurons in the recipient.

In many adult organisms, including humans, neurons in some parts of the brain are continually replenished. While this process is critical for ongoing health, dysfunctions in the production of new neurons may also contribute to several neurological diseases, including clinical depression and some neurodegenerative disorders.

Beltz notes, of course, that it is difficult to extrapolate from crayfish to human disease. However, because of existing research suggesting that stem cells harvested from bone marrow also can become neural precursors and generate neurons, she says it is tempting to suggest that the mechanism proposed in crayfish may also be applicable in evolutionarily higher organisms, perhaps even in humans.

Prior studies conducted in both humans and mice and published about a decade ago, showed that bone marrow recipients who had received a transplant from the opposite gender had neurons with the genetic signature of the opposite sex. The implication was that cells from the bone marrow generated those neurons. However, it is currently thought that neuronal stem cells in mammals, including humans, are self-renewing and therefore do not need to be replenished. Thus, these findings have not been interpreted as contributing to a natural physiological mechanism.

Every experiment we did confirmed the close relationship between the immune system and adult neurogenesis, Beltz said. Often when one is doing research, experiments can be fussy or give variable results. But for this work, once we started asking the right questions, the experiments worked first time and every time. The consistency and strength of the data are remarkable.

Our findings in crayfish indicate that the immune system is intimately tied to mechanisms of adult neurogenesis, suggesting a much closer relationship between the immune system and nervous system than has been previously appreciated, said Sderhll. If further studies demonstrate a similar relationship between the immune system and brain in mammals, these findings would stimulate a new area of research into immune therapies to target neurological diseases.

See more here:
Blood Cells Generate Neurons in Crayfish; Could Have Implications for Treatment of Neurodegenerative Disorders

A new research has suggested that immune cells, known as natural killer cells could help in hunting down and kill cancers that have spread in the body.

The study showed that a protein called MCL-1 was vital for survival of natural killer cells.

Dr. Nick Huntington said that they discovered that MCL-1 was absolutely essential for keeping natural killer cells alive and without natural killer cells, the body was unable to destroy melanoma metastases that had spread throughout the body, and the cancers overwhelmed the lungs.

Huntington said that the natural killer cells led the response that caused rejection of donor stem cells in bone marrow transplantations and they also produced inflammatory signals that could result in toxic shock syndrome, a potentially fatal illness caused by bacterial toxins that causes a whole-body inflammatory reaction.

The study is published in the journal Nature Communications.

(Posted on 15-08-2014)

View post:
'Killer' immune cells destroy body cancer

Immunologist Nick Huntington. Photo: Getty Images/Paul Jeffers

The bodys natural killer cells, as their Hollywood-style name suggests, are key to the immune system. They are programmed to hunt out and destroy foreign and diseased cells. But they dont always identify their targets. When this happens, diseases such as cancer can set in.

But a team of researchers at the Walter and Eliza Hall Institute of Medical Research have worked out what the group of highly specialised killer cells need to function at their best. Its a protein called MCL-1.

Immunologist Nick Huntington said the protein was effectively a switch which could turn the killer cells on or off.

The discovery, outlined on Thursday in the journal Nature Communications, opens the way for new drug treatments to tame the spread of a range of diseases, including cancer.

It could also assist patients who undergo donor stem cell or bone marrow transplants - because by manipulating the killer cells switch, foreign bodies such as stem cells could go unchallenged by the bodys immune system.

"Its the only protein which does this in the cell, Dr Huntington said. It needs to be turned on for the cell to survive and when its turned off the cell will die.

While aware of the existence of the MCL-1 protein and its importance at a fundamental level, scientists were previously unaware of its role in natural killer cell function. With colleagues Priyanka Sathe and Rebecca Delconte, Dr Huntington established its role.

That knowledge will prove useful for the development of new drugs to treat cancers.

Potential benefits include reduced side effects from treatment, as the killer cells only target foreign, diseased or cancerous cells, unlike chemotherapy which targets healthy cells as well.

Read the rest here:
Scientists discover killer cells' ''on switch''

Infusing stem cells into the brain may help boost recovery after a stroke, according to a pilot study by Imperial College London.

Scientists believe the cells encourage new blood vessels to grow in damaged areas of the brain.

They found most patients were able to walk and look after themselves independently by the end of the trial, despite having suffered severe strokes.

Larger studies are needed to evaluate whether this could be used more widely.

In this early trial - designed primarily to look at the safety of this approach - researchers harvested stem cells from the bone marrow of five people who had recently had a stroke.

'Independent living'

They isolated particular types of stem cells - known as CD34+. These have the ability to stimulate the growth of new blood vessels.

They were infused directly into damaged sections of the brain, via the major artery that supplies this area.

Scientists monitored the patients for six months, charting their ability to carry out everyday activities independently.

Four of the five patients had suffered particularly severe strokes - resulting in the loss of speech and marked paralysis down one side of the body.

Read the rest here:
'Stem Cells Show Promise In Stroke Recovery'

5 stroke victims were treated with stem cells extracted from bone marrow Treatment triggers rapid regeneration of damaged brain cells Patients regained power of speech and use of their arms and legs More than 150,000 people have a stroke in England every year Treatment is at early stage and needs years of testing Imperial College London scientists says it shows 'great potential'

By Ben Spencer

Published: 09:25 EST, 8 August 2014 | Updated: 19:30 EST, 8 August 2014

561 shares

19

View comments

Five people who had suffered severe strokes (illustrated) regained the power of speech and mobility thanks to a radical new treatment

Stroke patients have shown remarkable signs of recovery after they were given a radical new treatment.

Five people who had suffered severe strokes regained the power of speech, use of their arms and legs and improved cognition after just six months, according to British research published today.

The three men and two women, aged between 45 and 75, were treated with stem cells extracted from their own bone marrow in the first experiment of its kind.

Link:
Hope for stroke victims after radical stem cell treatment enables patients to move and talk again

A pilot study undertaken by researchers from Imperial College Healthcare NHS Trust and Imperial College London has shown promise in rapid treatment of serious strokes. The study, the first of its kind published in the UK, treated patients using stem cells from bone marrow.

Imagine a perfectly ordinary beginning to your day, say burned toast, no matching pair of socks and the usual damp commute to work. Except at some point through the usual minutiae you suffer a massive stroke. If you dont die outright, you may soon afterwards. Even supposing you survive those first days or weeks, the chance of your life resuming its comforting tedium is impossibly remote. You may need assistance for the rest of your shortened life.

According to the Stroke Association, about 152,000 people suffer a stroke in the UK alone each year. However, the five patients treated in the recent Imperial College pilot study all showed improvements. According to doctors, four of those had suffered the most severe kind of stroke, which leaves only four percent of people alive or able to live independently six months after the event. All four of the patients were alive after six months.

A particular set of CD34+ stem cells was used, as they help with the production of blood cells and blood vessels lining cells. These same cells have been found to improve the effects of stroke in animals, and they assist in brain tissue and blood growth in the affected areas of the brain. The CD34+ cells were isolated from samples taken from patients bone marrow and then infused into the affected area via an artery that leads to the brain, using keyhole surgery.

The innovative stem cell treatment differs from others in one important way: patients are treated within seven days of their stroke, rather than six months hence. The stroke sufferers all recorded improvements in terms of clinical measures of disability, despite four of the five having suffered the most severe kind of stroke.

It's still early days for the research, and much more will need to be done to expand clinical trials, but eventually it is hoped that a drug may be developed that can be administered to stroke sufferers as soon as they are admitted to hospital. This could ameliorate longer term effects and allow for speedier recovery and a faster entry into therapy.

A paper detailing the research was published in journal Stem Cells Translational Medicine.

Source: Imperial College London

More here:
Stem cell stroke therapy shows promise after first human trial

Union Health Minister Harsh Vardhan Wednesday called upon citizens to voluntarily register themselves as bone marrow donors to help enhance the chances of patients with blood cancer and other blood-related diseases get genetically compatible donors.

"Unlike blood donation, in the case of unrelated donor, the chances are one in a million that a donor's Human Leukocyte Antigen (HLA) will match with the needy patient's. Therefore, there is a requirement of having millions of registered donors," Vardhan said while speaking at the launch of a "Public Initiative of Bone Marrow Donation" at All India Institute of Medical Science (AIIMS) here.

A willing donor can register himself at the Asian Indian Donor Marrow Registry (AIDMR) at AIIMS. He will have to undergo an initial test done for which 10 ml of blood is taken. The test is called HLA typing.

In case they turn out to be HLA match for the needy patient, they will be requested to donate their bone marrow or peripheral blood stem cells to patients of blood-cancer and other disorders, he said.

Vardhan said the health ministry will soon start a facility for the bone marrow donation in Safdurjung Hospital, which will intensify the initiative for bone marrow donation in the country.

"There is a need for the NGOs and several other health organisations to spread awareness in the society to curb all kinds of myths and superstitions that deter the individuals from being donors, which is a noble cause," he said.

On the occasion, Vardhan registered himself as a bone marrow donor and gave his blood sample for the HLA testing.

"One should at least understand that for the patients suffering from blood-related diseases like blood cancer, leukaemia, thalassemia, anaemia and many other diseases, a simple commitment to donate bone marrow can save a patient's life at the cost of nothing," Vardhan told IANS.

The AIDMR at AIIMS has set a target of registering 100,000 bone marrow donors in the first year and expand the register up to half a million donors in the next five years.

Vardhan also called for donation of body organs and cadavers, which can save life of the needy patients, and also serve the purposes of medical research.

Follow this link:
India needs more bone marrow donors: Harsh Vardhan

Brain damage caused by strokes could be repaired through the use of stem cells in a discovery that may revolutionise treatment, a study has suggested.

Researchers at Imperial College London found that injecting a patient's stem cells into their brain may be able to change the lives of the tens of thousands of people who suffer strokes each year.

Their results have been called "one of the most exciting recent developments in stroke research".

Doctors said the procedure could become routine in 10 years after larger trials are conducted to examine its effectiveness.

Researcher Dr Paul Bentley, from the college's Department of Medicine, said: "Currently, the main form of treatment is an unblocking of the blood vessel, and that only helps one-third of the patients who are treated and only 10 per cent are eligible anyway. So we said, 'What about the other 90 per cent?' "

The team targeted patients who had suffered severe strokes involving a clot in a blood vessel in the middle of the brain. Typically, there is a high mortality rate in these patients and those who survive are often severely disabled, unable to walk, talk, feed or dress themselves. The experimental procedure was carried out on five such patients, aged 40 to 70, all of whom showed improvement over the following six months, and three were living independently.

Dr Madina Kara, a neuroscientist at the Stroke Association, said: "This is one of the most exciting recent developments in stroke research. However, it's still early days in stem cell research, but the findings could lead to new treatments for stroke patients in the future.

"In the UK, someone has a stroke every three and a half minutes, and around 58 per cent of stroke survivors are left with a disability."

The experimental procedure involved harvesting the patient's own bone marrow, which was then sent to a specialist laboratory so specific stem cells, called CD34+, could be selected. The patient then has a wire inserted into the area of the brain damage. Once there, the stem cells are released and the wire retracted. During the trials the whole process took half a day, but it is hoped that with refinement it could be reduced.

It is thought the cells work in two ways: by growing into small blood vessels that allow the brain to grow new nerves and brain tissue surrounding them, and by releasing anti-inflammatory chemicals that encourage tissue repair.

Originally posted here:
Stem cell hope for stroke victims

MONTREALA Quebec womans desperate online plea for a compatible stem-cell donor in her bid to fight cancer a second time is shedding light on the lack of minorities on official lists in Canada and abroad.

Mai Duong finds herself battling leukemia again and doctors say they would like to proceed with a transplant of bone marrow or cord blood stem cells within a month.

But Duong, 34, has discovered that locating the right person can be a needle-in-a-haystack challenge, particularly for those who are from a non-Caucasian background.

This is a global problem, Duong, who is of Vietnamese origin, said in an interview from her room at Montreals Maisonneuve-Rosemont Hospital.

We cant do a scavenger hunt every time someone has this type of problem.

Duong, who returned home a few days after being interviewed, said a recent bone marrow biopsy showed no signs of cancer. She will now begin four weeks of maintenance chemotherapy, which is given in lower doses to assist in prolonging a remission.

The mother of a 4-year-old girl, Duong successfully fought off acute leukemia in 2013 with chemotherapy. She had to terminate a 15-week pregnancy to undergo the treatment. Duong was in remission until a blood test revealed leukemia had returned this past May.

Seventy per cent of people who had that type of leukemia were just cured with chemotherapy, and unfortunately Im in the 30 per cent, she said.

The diagnosis and a lack of a match in her family have touched off a mad scramble to find a fellow Vietnamese donor. An online campaign has taken that hunt global.

I have cancer, I had a relapse, I dont have a bone marrow (donor) these are things I cannot change, Duong said. So I said, what can I do about it?

See the article here:
Quebec womans leukemia battle highlights need for minority bone marrow and stem cell donors

By Sidhartha Banerjee, The Canadian Press Published Saturday, August 2, 2014 8:56AM EDT

MONTREAL -- A Quebec woman's desperate online plea for a compatible stem-cell donor in her bid to fight cancer a second time is shedding light on the lack of minorities on official lists in Canada and abroad.

Mai Duong finds herself battling leukemia again and doctors say they would like to proceed with a transplant of bone marrow or cord blood stem cells within a month.

But Duong, 34, has discovered that locating the right person can be a needle-in-a-haystack challenge, particularly for those who are from a non-Caucasian background.

"This is a global problem," Duong, who is of Vietnamese origin, said in an interview from her room at Montreal's Maisonneuve-Rosemont Hospital.

"We can't do a scavenger hunt every time someone has this type of problem."

Duong, who returned home a few days after being interviewed, said a recent bone marrow biopsy showed no signs of cancer. She will now begin four weeks of maintenance chemotherapy, which is given in lower doses to assist in prolonging a remission.

The mother of a four-year-old girl, Duong successfully fought off acute leukemia in 2013 with chemotherapy. She had to terminate a 15-week pregnancy to undergo the treatment. Duong was in remission until a blood test revealed leukemia had returned this past May.

"Seventy per cent of people who had that type of leukemia were just cured with chemotherapy and unfortunately I'm in the 30 per cent," she said.

The diagnosis and a lack of a match in her family has touched off a mad scramble to find a fellow Vietnamese donor. An online campaign has taken that hunt global.

More:
Cancer fight shows lack of minorities on donor lists

Following the death of their colleague Marlon Layne, members of the marketing firm Ogilvy and Mather started a campaign to get the word out about the prevalence of blood cancers and the need for more diversity within the donor pool. Over the past three years they've raised nearly $42,000 for the cause and signed up around 160 new donors to the Be the Match Registry.

"I cant change the past but I can ensure that in the future nobody else like Marlon has to be waiting for a marrow registrant from somebody whos of their same race," said Ogilvy & Mather Marketing Analytics Associate Director Omari Jinaki.

But Jinaki says he has noticed a level of hesitancy to participate within the Black community.

"That is rooted, clearly, in hundreds of years of history of being misguided and misrepresented and underrepresented by the systems that are supposed to protect us," said Jinaki.

There's also a lack of awareness of the need within the Latino and Asian communities and lingering misconceptions the donation process- many believing it's painful with significant recovery time.

"The process has changed in the way one donates bone marrow. 75 percent of the time it's just like a blood donation," said Icla Da Silva Foundation President Airam Da Silva.

Depending on the recipient's need- most can now donate via a peripheral blood stem cell or PBSC.

For five days before donation, the donor is injected with filgrastim, which moves more blood-forming cells out of the marrow into the blood stream. The drug can cause head or joint aches and fatigue.

"On the fifth day the donor goes to the blood bank or to the hospital, they donate blood from one arm, the blood goes through a apheresis machine where it separates the bone marrow cells and the rest of the blood goes back on the other arm," said Da Silva.

You can also donate through a surgical procedure- with general or regional anesthesia. Doctors use hollow needles to draw liquid marrow from the back of the pelvic bone. Donors are usually sent home the same or the following day and feel some soreness for around a week after the procedure.

Go here to read the rest:
Group Raising Awarness about Need for Bone Marrow Donors

SINGAPORE - Singapore's life-saving Bone Marrow Donor Programme celebrated its 100th donor and new patron, Minister for Law and Foreign Affairs K Shanmugam, on Thursday.

Get the full story from The Straits Times.

Here is the statement from the Bone Marrow Donor Programme:

The Bone Marrow Donor Programme (BMDP) celebrates 21 years of saving lives through an extraordinary gift of kindness and generosity as ordinary Singaporeans commit to helping a fellow human being.

As bone marrow transplants become the preferred treatment for a wide number of blood related diseases such as leukaemia and lymphoma, the new BMDP Patron, Minister K Shanmugam, Minister for Law and Foreign Affairs and MP for Nee Soon GRC gave an award to the 100th Singaporean bone marrow donor, Lim Yun Song a 27 year-old Engineer and NTU graduate. This was in recognition of the commitment he and all the other bone marrow donors have made in a purely voluntary capacity to give of themselves a priceless gift of bone marrow (blood stem cells) to save the life of a stranger.

The BMDP manages Singapore's only registry of bone marrow donors and can literally be the last chance of survival for patients with terminal blood-related illnesses. Sadly, though, the chance of finding a donor whose DNA profile is a match to the patient is an alarming 1 in 20,000. With Singapore's unique and rapidly changing demographic, it is more important than ever to recruit more volunteers to join the registry and make sure that each patient is given this last chance of survival.

In conjunction with the 21st anniversary and office inauguration, the BMDP shared a number of significant milestones achieved in recent months.

In addition to reaching the 100th local donor, the number of local donors identified as a patient match increased from 38 in 2012 to 73 last year and year-to-date 64 donors were called up for Confirmatory Typing.

In tandem, the number of volunteers actually going through to make their life-saving donation has increased from seven in the whole of 2013, to nine in the first half of this year with more scheduled.

Minister Shanmugam says, "Bone marrow donors are heroes. They are given a chance to help a fellow human being through a simple yet selfless act of kindness - and they take it. This opportunity is available to everyone but so few rise to the challenge and I hope that more young people - the future of Singapore - will be inspired by what we are seeing here today and will sign up as volunteer bone marrow donors. I'm honoured to join the BMDP as their Patron, and look forward to working with them to build our community of heroes".

View original post here:
Bone marrow donor programme celebrates 100 donors and new patron

Health and Medicine for Seniors

Aging Immune System May Get Kick-Start from Discovery of Molecular Defect

Old stem cells are not just sitting there with damaged DNA ready to develop cancer, as it has long been postulated

"The decline of stem-cell function is a big part of age-related problems. Achieving longer lives relies in part on achieving a better understanding of why stem cells are not able to maintain optimal functioning."

Emmanuelle Passegu, PhD

July 31, 2014 - There's a good reason seniors over 60 are not donor candidates for bone marrow transplantation. The immune system ages and weakens with time, making the elderly prone to life-threatening infection and other maladies, and a UC San Francisco research team now has discovered a reason why.

"We have found the cellular mechanism responsible for the inability of blood-forming cells to maintain blood production over time in an old organism, and have identified molecular defects that could be restored for rejuvenation therapies," said Emmanuelle Passegu, PhD, a professor of medicine and a member of the Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research at UCSF.

Passegu, an expert on the stem cells that give rise to the blood and immune system, led a team that published the new findings online July 30, 2014 in the journal Nature.

Blood and immune cells are short-lived, and unlike most tissues, must be constantly replenished. The cells that must keep producing them throughout a lifetime are called "hematopoietic stem cells."

Through cycles of cell division these stem cells preserve their own numbers and generate the daughter cells that give rise to replacement blood and immune cells. But the hematopoietic stem cells falter with age, because they lose the ability to replicate their DNA accurately and efficiently during cell division, Passegu's lab team determined.

View original post here:
Aging Immune System May Get Kick-Start from Discovery of Molecular Defect